Human VIP-α: An emerging biologic response modifier to treat primary pulmonary hypertension

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 4, 2005, Pages 565-569

  Rubinstein, Israel ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

cGMP; Drug delivery; Liposomes; Micelles; Microcirculation; Neuropeptide; Nitric oxide; PPH; Proteolysis; Vascular smooth muscle; Vasoactive intestinal peptide; Vasodilation

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHOLIPID; PROSTACYCLIN DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASODILATOR AGENT;

ARTICLE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STABILITY; HUMAN; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASOCONSTRICTION; MICELLE; NONHUMAN; PULMONARY HYPERTENSION; SHELF LIFE; SIDE EFFECT; VEIN THROMBOSIS;

BIOLOGICAL RESPONSE MODIFIERS; HUMANS; HYPERTENSION, PULMONARY; VASOACTIVE INTESTINAL PEPTIDE;

EID: 23144449186     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.4.565     Document Type: Article

References (46)

1. Fishman AP. Primary pulmonary arterial hypertension: a look back. J. Am. Coll. Cardiol. 43(Suppl. 12), 2S-4S (2004).
2. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 22, 358-363 (2003).
3. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 157, 219-229 (1998).
4. Damas JK, Otterdal K, Yndestad A et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110, 999-1005 (2004).
5. Nagaya N. Drug therapy of primary pulmonary hypertension. Am. J. Cardiovasc. Drugs 4, 75-85 (2004)
6. Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111, 1339-1346 (2003).
7. Keith IM. The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol. Res. 49, 519-537 (2000).
8. Busto R, Prieto JC, Bodega G, Zapatero J, Carrero I. Immuno-histochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 21, 265-269 (2000).
9. Busto R, Carrero I, Guijarro LG et al. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung. Am. J. Physiol. 277, L42-L48 (1999).
10. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans. Assoc. Am. Physicians 97, 304-310 (1984).
11. Greenber B, Rhoden K, Barnes PJ. Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries. Blood Vessels 24, 45-50 (1987).
12. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Res. 56, 249-290 (2004).
13. Thom SM, Hughes AD, Goldberg P, Martin G, Schachter M, Sever PS. The actions of calcitonin gene related peptide and vasoactive intestinal peptides as vasodilators in man in vivo and in vitro. Br. J. Clin. Pharmacol. 24, 139-144 (1987).
14. Greenberg B, Rhoden K, Barnes PJ. Endothelium-dependent relaxation of human pulmonary arteries. Am. J. Physiol. 252, H434-H438 (1987).
15. Leys K, Morice AH, Madonna O, Sever PS. Autoradiographic localization of VIP receptors in human lung. FEBS Lett. 199, 198-202 (1986).
16. Dey RD, Shannon WA Jr, Said SI. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res. 220, 231-238 (1981).
17. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptides? Faseb J. 18, 1325-1334 (2004).
18. Söderman C, Eriksson LS, Juhlin-Dannfelt A, Lundberg JM, Broman L, Holmgren A. Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects. Clin. Physiol. 13, 677-685 (1993).
19. Delgado M. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J. Biol. Chem. 278, 27620-27629 (2003).
20. Cox CP, Linden J, Said SI. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 5, 325-328 (1984).
21. Konttinen Y, Imai S, Suda A. Neuropeptides and the puzzle of bone remodeling. State of the art. Acta Orthop. Scand. 67, 632-639 (1996).
22. Zwerina J, Landsteiner H, Leitgeb U et al. The influence of VIP and epoprostenol on platelet CD62P expression and primary haemostasis in vitro. Platelets 15, 55-60 (2004).
23. Gozes I, Furman S. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract. Res. Clin. Endocrinol. Metab. 18, 623-640 (2004).
24. Chongsrisawat V, Ampai S, Chotivitayatarakorn P, Sirisopikul T, Poovorawan Y. Relationship between vasoactive intestinal peptide and intrapulmonary vascular dilatation in children with various liver diseases. Acta paediatr. 92, 1411-1414 (2003).
25. Eriksson LS, Hagenfeldt L, Mutt V, Wahren J. Influence of vasoactive intestinal polypeptide (VIP) on splanchnic and central hemodynamics in healthy subjects. Peptides 10, 481-484 (1989).
26. Virgolini I, Raderer M, Kurtaran A et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331, 1116-1121 (1994).
27. Schmidt DT, Rühlmann E, Waldeck B et al. The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn-Schmiedeberg's Arch. Pharmacol. 364, 314-320 (2001).
28. Gao X-p, Noda Y, Rubinstein I, Paul S. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure. Life Sci. 54, PL247-PL252 (1994).
29. Suzuki H, Noda Y, Gao X-P et al. Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ. Am. J. Physiol. 271, H282-H287 (1996).
30. Séjourné F, Suzuki H, Alkan-Önyüksel H, Gao X-p, Ikezaki H, Rubinstein I. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo. Am. J. Physiol. 273, R287-R292 (1997).
31. Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 285, 753-758 (1998).
32. Ikezaki H, Paul S, Alkan-Önyüksel H, Patel M, Gao X-P, Rubinstein I. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster check pouch. Am. J. Physiol. 275, R56-R62 (1998).
33. Ikezaki H, Alka-Önyüksel H, Rubinstein I. Liposomal VIP attenuates phenylephrine- and angiotensin II-induced vasoconstriction. in vivo. Am. J. Physiol. 275, R588-R595 (1998).
34. Önyüksel H, Ikezaki H, Patel M, Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res. 16, 155-160 (1999).
35. Ikezaki H, Patel M, Önyüksel H, Akhter SR, Rubinstein I. Exogenous calmodulin potentiates vasodilation elicited by phospholipid-associated VIP in vivo. Am. J. Physiol. 276, R1359-R1365 (1999).
36. Séjourné F, Rubinstein I, Suzuki H, Alkan-Önyüksel H. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm. Res. 14, 362-365 (1997).
37. Rubinstein I, Patel M, Ikezaki H, Dagar S, Önyüksel H. Conformation and vasoreactivity of VIP in phospholipid micelles: effects of calmodulin. Peptides 20, 1497-1501 (1999).
38. Önyüksel H, Bodalia B, Sehti V, Dagar S, Rubinstein I. Surface-active properties of vasoactive intestinal peptide. Peptides 21, 419-423 (2000).
39. Tsueshita T, Gandhi S, Önyüksel H, Rubinstein I. Phospholipids modulate the biophysical properties and vasoactivity of PACAP(1-38). J. Appl. Physiol. 93, 1377-1383 (2002).
40. Yeomans DC, Önyüksel, Dagar S, Ikezaki H, Lu Y, Rubinstein I. Conformation-dependent effects of VIP on nociception in rats. Peptides 24, 617-622 (2003).
41. Önyüksel H, Ashok B, Dagar S, Sethi V, Rubinstein I. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity. Peptides 24, 281-286 (2003).
42. Ashok B, Rubinstein I, Tsueshita T, Önyüksel H. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP1-38 in pegylated phospholipid micelles. Peptides 25, 1253-1258 (2004).
43. Sethi V, Önyüksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol 391, 377-395 (2005).
44. 131I-VIP in rat using gamma camera. Nucl. Med. Biol. 26, 931-936 (1999).
45. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319-328 (2003).
46. Otto C, Hein L, Brede M et al. Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110, 3245-3251 (2004).